Welcome!

News Feed Item

PDI Reports 2014 Second Quarter Financial Results

Management Will Host Conference Call Tomorrow August 14 at 8:30 am ET

PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the second quarter ended June 30, 2014. Summary financial and operational accomplishments include:

  • Revenue of $31.6 million for the second quarter of 2014
  • Adjusted EBITDA (a non-GAAP financial measure) of $(1.5) million for the second quarter of 2014
  • On August 13, 2014, PDI acquired Asuragen, Inc.'s miRInform Thyroid and miRInform Pancreas cancer test assets
  • Subsequent to the second quarter, Heiner Dreismann, Ph.D., a highly experienced molecular diagnostics executive and former President and CEO of Roche Molecular Systems, joined PDI's board of directors
PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise.

 

 

Condensed Summary Statements of Continuing Operations (Unaudited)

($'s in thousands, expect per share data)










2nd Quarter Ended


Six Months Ended




June 30,*


June 30,*




2014


2013


2014


2013











Revenue, net


$           31.6


$           37.2


$           64.4


$           80.2











Gross profit


4.8


6.8


9.9


15.3











Operating expenses:









   Compensation expense

3.9


4.9


7.4


9.1

   Other SG&A


3.5


2.8


6.5


4.8

         Total operating expenses

7.3


7.7


13.9


13.9











Operating (loss) income 

$           (2.5)


$            (0.8)


$           (4.0)


$             1.4











Provision for income tax

0.1


0.1


0.1


0.1

(Loss) income from continuing operations

$           (2.6)


$            (0.9)


$           (4.2)


$             1.2











Diluted (loss) income per share from continuing operations

$         (0.17)


$          (0.06)


$         (0.28)


$           0.08

  *Unaudited









 

CEO Comments

"We are extremely excited to announce the agreement to acquire specific diagnostic assets from Asuragen, Inc. The transaction is the first step for our Interpace Diagnostic subsidiary in expanding into higher growth, higher margin markets and starts to establish Interpace as a commercially focused molecular diagnostic subsidiary," said Nancy Lurker, CEO.

"The transaction includes two oncology assays, miRInform Thyroid and miRInform Pancreas, associated intellectual property, a large biobank with over 5,000 patient tissue samples, as well as, additional thyroid tests in development."

"In addition, Heiner Dreismann, Ph.D., has joined our board of directors and brings with him nearly 30 years of experience in the diagnostic industry and extensive background in molecular diagnostics including his former tenure as President and CEO of Roche Molecular Systems. We look forward to his invaluable insight as we continue to evolve as a company."

"In terms of second quarter results, our revenue of $32 million were in line with our expectations and continues to reflect the soft RFP volume we experienced in our Sales Services business. Gross margins of 15%, while down compared to last year, are in line with current industry norms. Our adjusted EBITDA loss of $1.5 million in the quarter was primarily driven by spending on our key strategic initiatives and lower gross profit," said Nancy Lurker, CEO.

Ms. Lurker continued, "As for our outlook for the remainder of the year, we continue to expect revenue in our core business to be down in the third quarter and for the full year compared to 2013. We still anticipate an operating loss in the range of $4 - $5 million and approximately breakeven adjusted EBITDA in the core business for the full year 2014. Given today's Asuragen transaction, we now see a modest amount of revenues from Interpace Diagnostic for 2014 and an operating loss in the range of $5 - $6 million from all Interpace Diagnostics activities including additional selling and marketing and pre-launch expenses to support the anticipated ramp up of revenue from the acquired Asuragen assets."

Second Quarter Business Review

Revenue- For the second quarter of 2014, revenue of $31.6 million was $5.7 million or 15% lower than the second quarter of 2013 driven by the natural expiration or reduction of contracts being executed in 2014 exceeding new contracts entered into in the company's Sales Services segment.

  • Sales Services revenue of $28.1 million was $4.2 million lower than the second quarter of 2013. New contract wins from the softer RFP volume experienced in the latter half of 2013 was not sufficient to offset the natural expiration or reduction of certain contracts.

  • Marketing Services revenue of $0.6 million was $1.0 million lower than the second quarter of 2013 due to fewer contract signings by Group DCA.

  • Product Commercialization Services revenue of $2.9 million was $0.4 million lower than the second quarter of 2013.

Gross Profit- For the second quarter of 2014, gross profit of $4.8 million was $2.1 million lower than the second quarter of 2013 and, as anticipated, the overall gross profit percentage decreased to 15% in 2014 from 18% in 2013.

  • Sales Services gross profit of $4.8 million was $0.5 million lower than the second quarter of 2013 due primarily to lower revenue and previously disclosed competitive pricing pressures.

  • Marketing Services gross profit for the second quarter of 2014 was a negative $0.5 million due to the decrease in revenue and increased costs associated with the launch of our new product, PD One.

  • Product Commercialization Services gross profit of $0.6 million was $0.4 million lower compared to the second quarter of 2013 primarily due to expenses related to one of our collaboration agreements for molecular diagnostic tests.

Total Operating Expenses- Total operating expenses for the second quarter of 2014 were $7.3 million as compared to $7.7 million for the same period in 2013. Included in second quarter 2014 expenses are $0.7 million of investment costs related to our molecular diagnostics strategic initiative. Excluding these costs, total operating expenses for the second quarter of 2014 were $6.6 million; $1.1 million lower than 2013 operating expenses.

Operating Income/Loss- The operating loss for the second quarter of 2014 was $2.5 million, compared to $0.8 million for the same period in 2013.  The 2014 operating loss was primarily the result of the anticipated lower revenue and margins as well as the company's investment in strategic initiatives.

Liquidity and Cash Flow- Adjusted EBITDA (a non-GAAP measure defined in the release) for the second quarter of 2014 was $(1.5) million compared to $0.2 million in the second quarter of 2013. Cash and cash equivalents at the end of the second quarter were $35.6 million, down $10.0 million from December 31, 2013 due primarily to increases in working capital requirements, timing of certain payments from customers and investments in our strategic initiatives. Factoring in the Asuragen acquisition and anticipated additional spending in Interpace Diagnostics, the company estimates year end 2014 cash of $22 - $25 million.

As of June 30, 2014, the company's cash equivalents were predominantly invested in U.S. Treasury money market funds and the company had no commercial debt.

Non-GAAP Financial Measures

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, PDI has provided a certain non-GAAP financial measure to help evaluate the results of its performance. The company believes that this non-GAAP financial measure, when presented in conjunction with comparable GAAP financial measure, is useful to both management and investors in analyzing the company's ongoing business and operating performance. The company believes that providing non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the company's financial results in the way that management views financial results.

In this document, the company discusses Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as operating income or loss, plus depreciation and amortization, non-cash stock-based compensation, and other non-cash expenses. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

Adjusted EBITDA (Unaudited)

($ in thousands)




2nd Quarter Ended


Six Months Ended




June 30,


June 30,




2014


2013


2014


2013











Operating (loss) income 

$       (2,523)


$           (847)


$       (4,020)


$         1,406

Depreciation and amortization

380


289


837


577

Stock compensation


668


722


1,358


1,073

Adjusted EBITDA


$       (1,475)


$            164


$       (1,825)


$         3,056

 

Conference Call

As previously announced, PDI will hold a conference call Thursday, August 14, 2014 to discuss financial and operational results of the second quarter ended June 30, 2014.  Details as follows:

Time: 8:30 AM (ET)
Dial-in numbers: (855) 592-8761 (U.S. and Canada) or (724) 924-4975
Conference ID#: 27904432

Live webcast: www.pdi-inc.com, under "Investor Relations"

The teleconference replay will be available three hours after completion through September 13, 2014 at (855) 859-2056 (U.S. and Canada) or (404) 537-3406. The replay pass code is 27904432. The archived web cast will be available for one year.

About PDI, Inc.

PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. PDI's Interpace Diagnostics division is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company's Contract Sales business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. Its Group DCA division is a pioneer in insight-driven digital communication services and integrated multichannel message delivery.

For more information about PDI, Inc. or Interpace Diagnostics, please visit http://www.pdi-inc.com and www.interpacediagnostics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, growth and profitability, actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers or the inability to secure additional business. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's previously filed Annual Report on Form 10-K for the year ended December 31, 2013 and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

PDI, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(in thousands, except per share data)










Three Months Ended


Six Months Ended


June 30,


June 30,


2014


2013


2014


2013









Revenue, net

$         31,578


$         37,245


$      64,356


$        80,168

Cost of services

26,787


30,396


54,456


64,846

Gross profit

4,791


6,849


9,900


15,322









Compensation expense

3,862


4,914


7,403


9,069

Other selling, general and administrative expenses

3,452


2,782


6,517


4,847

Total operating expenses

7,314


7,696


13,920


13,916

Operating (loss) income 

(2,523)


(847)


(4,020)


1,406

Other expense, net

(13)


(24)


(30)


(34)

(Loss) income from continuing operations before








income tax

(2,536)


(871)


(4,050)


1,372

Provision for income tax

65


64


131


128

(Loss) income from continuing operations

(2,601)


(935)


(4,181)


1,244

(Loss) income  from discontinued operations, net of tax

(57)


52


(89)


(2)









Net (loss) income 

$          (2,658)


$             (883)


$       (4,270)


$          1,242









Basic (loss) income per share of common stock:








From continuing operations

$            (0.17)


$            (0.06)


$         (0.28)


$             0.08

From discontinued operations

(0.01)


-


(0.01)


-

Net (loss) income per basic share of common stock

$            (0.18)


$            (0.06)


$         (0.29)


$             0.08









Diluted (loss) income per share of common stock:








From continuing operations

$            (0.17)


$            (0.06)


$         (0.28)


$             0.08

From discontinued operations

(0.01)


-


(0.01)


-

Net (loss) income per diluted share of common stock

$            (0.18)


$            (0.06)


$         (0.29)


$             0.08









Weighted average number of common shares and








common share equivalents outstanding:








Basic

14,910


14,713


14,860


14,691

Diluted

14,910


14,713


14,860


15,154

 

Segment Data (Unaudited)

($ in thousands)










Sales


Marketing


PC



Services


Services


Services*


Consolidated

Three months ended June 30, 2014:








Revenue, net

$         28,067


$              614


$        2,897


$        31,578

Gross profit (loss)

$           4,765


$            (526)


$           552


$          4,791

Gross profit %

17.0%


-85.7%


19.1%


15.2%









Three months ended June 30, 2013:








Revenue, net

$         32,294


$           1,644


$        3,307


$        37,245

Gross profit

$           5,252


$              638


$           959


$          6,849

Gross profit %

16.3%


38.8%


29.0%


18.4%










Sales


Marketing


PC



Services


Services


Services*


Consolidated

Six months ended June 30, 2014:








Revenue, net

$         56,862


$          1,617


$        5,877


$        64,356

Gross profit (loss)

$           9,508


$            (694)


$        1,086


$          9,900

Gross profit %

16.7%


-42.9%


18.5%


15.4%









Six months ended June 30, 2013:








Revenue, net

$         70,519


$          3,185


$        6,464


$        80,168

Gross profit

$         12,571


$          1,022


$        1,729


$        15,322

Gross profit %

17.8%


32.1%


26.7%


19.1%









* Product Commercialization (PC) Services



 

 

Selected Balance Sheet Data (Unaudited)

($ in thousands)


 June 30, 


 December 31, 


2014


2013





Cash and cash equivalents

$         35,621


$         45,639





Total current assets

$         53,176


$         62,709

Total current liabilities

25,621


31,400

Working capital

$         27,555


$         31,309





Total assets

$         59,459


$         69,064

Total liabilities

$         30,107


$         36,585

Total stockholders' equity

$         29,352


$         32,479









Selected Cash Flow Data (Unaudited)

($ in thousands)


June 30,


2014


2013





Net (loss) income

$       (4,270)


$        1,242

Non-cash items:




     Depreciation and amortization

837


577

     Stock-based compensation

1,358


1,073

     Other

71


71

Net change in assets and liabilities

(6,284)


(3,537)

Net cash used in operations

$       (8,288)


$         (574)





Change in cash and cash equivalents

$     (10,018)


$      (1,760)

Logo - http://photos.prnewswire.com/prnh/20140114/NY45872LOGO

SOURCE PDI, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
Contextual Analytics of various threat data provides a deeper understanding of a given threat and enables identification of unknown threat vectors. In his session at @ThingsExpo, David Dufour, Head of Security Architecture, IoT, Webroot, Inc., discussed how through the use of Big Data analytics and deep data correlation across different threat types, it is possible to gain a better understanding of where, how and to what level of danger a malicious actor poses to an organization, and to determin...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
Digital transformation has increased the pace of business creating a productivity divide between the technology haves and have nots. Managing financial information on spreadsheets and piecing together insight from numerous disconnected systems is no longer an option. Rapid market changes and aggressive competition are motivating business leaders to reevaluate legacy technology investments in search of modern technologies to achieve greater agility, reduced costs and organizational efficiencies. ...
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
"We do one of the best file systems in the world. We learned how to deal with Big Data many years ago and we implemented this knowledge into our software," explained Jakub Ratajczak, Business Development Manager at MooseFS, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Traditional IT, great for stable systems of record, is struggling to cope with newer, agile systems of engagement requirements coming straight from the business. In his session at 18th Cloud Expo, William Morrish, General Manager of Product Sales at Interoute, will outline ways of exploiting new architectures to enable both systems and building them to support your existing platforms, with an eye for the future. Technologies such as Docker and the hyper-convergence of computing, networking and...
Containers, microservices and DevOps are all the rage lately. You can read about how great they are and how they’ll change your life and the industry everywhere. So naturally when we started a new company and were deciding how to architect our app, we went with microservices, containers and DevOps. About now you’re expecting a story of how everything went so smoothly, we’re now pushing out code ten times a day, but the reality is quite different.
The hierarchical architecture that distributes "compute" within the network specially at the edge can enable new services by harnessing emerging technologies. But Edge-Compute comes at increased cost that needs to be managed and potentially augmented by creative architecture solutions as there will always a catching-up with the capacity demands. Processing power in smartphones has enhanced YoY and there is increasingly spare compute capacity that can be potentially pooled. Uber has successfully ...
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
You want to start your DevOps journey but where do you begin? Do you say DevOps loudly 5 times while looking in the mirror and it suddenly appears? Do you hire someone? Do you upskill your existing team? Here are some tips to help support your DevOps transformation. Conor Delanbanque has been involved with building & scaling teams in the DevOps space globally. He is the Head of DevOps Practice at MThree Consulting, a global technology consultancy. Conor founded the Future of DevOps Thought Leade...
When building large, cloud-based applications that operate at a high scale, it’s important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. “Fly two mistakes high” is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Lee A...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...